NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NASDAQ:PSTI - News) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that it has been chosen to present at the First Annual Israeli Presidential Conference termed “Facing Tomorrow", to be held on May 13-15, 2008 in Jerusalem.

The conference will focus on Jewish and Israeli contributions to humanity and will showcase 60 (for the 60^th anniversary of the State of Israel), meticulously selected out of hundreds, inventions and innovations developed by Israeli scientists, researchers and inventors, that have the potential to revolutionize the future for Israel and the world community alike.

World leaders, artists, scientists and entrepreneurs will take part in the event. Confirmed conference participants include President George W. Bush, Former British Prime Minister Tony Blair; Former President of the USSR Mikhail Gorbachev; Former US Secretary of State Dr. Henry Kissinger; New York Times columnist Thomas L. Friedman; Chairman and CEO of News Corporation Rupert Murdoch; and Harvard Law Professor Alan Dershowitz.

Zami Aberman, Pluristem’s President & CEO, stated: “Pluristem is pleased to be invited to this high level international conference to present its business and products in development to world-renowned business leaders, technology thought leaders and entrepreneurs.”

About Pluristem

Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of a number of severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial, non-embryonic, adult stem cell source.

These placental mesenchymal stromal cells (MSCs) are expanded in the Company’s proprietary PluriX™ 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. Pluristem believes the resultant PLX (PLacental eXpanded) cells are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and have immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.

Pluristem’s first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company’s products in development also include the PLX-I, targeting the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; the PLX-STROKE, targeting ischemic stroke; and the PLX–MS, targeting Multiple Sclerosis.

Pluristem has offices in the USA, with headquarters housing its R&D and GMP-approved manufacturing facilities in Haifa, Israel.

See our product animation on YouTube: http://www.youtube.com/watch?v=OFhWXyJT6Us.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.

Pluristem Therapeutics Inc.
William Prather RPh, MD
Sr. VP Corporate Development
303-883-4954
bill@pluristem.com